Literature DB >> 21815749

Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.

Lotte B Bertelsen1, Yuan Yuan Shen, Thomas Nielsen, Hans Stødkilde-Jørgensen, G Kenneth Lloyd, Dietmar W Siemann, Michael R Horsman.   

Abstract

PURPOSE: This study investigated the anti-tumour effects of the novel vascular disrupting agent plinabulin (NPI-2358) when given alone or combined with radiation.
MATERIALS AND METHODS: Foot implanted C3H mammary carcinomas or leg implanted KHT sarcomas were used, with plinabulin injected intraperitoneally. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measurements were made with gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) on a 7-tesla magnet. Treatment response was assessed using regrowth delay (C3H tumours), clonogenic survival (KHT sarcomas) or histological estimates of necrosis for both models.
RESULTS: Plinabulin (7.5 mg/kg) significantly reduced the initial area under curve (IAUC) and the transfer constant (K(trans)) within 1 hour after injection, reaching a nadir at 3 h, but returning to normal within 24 h. A dose-dependent decrease in IAUC and K(trans), was seen at 3 h. No significant anti-tumour effects were observed in the C3H tumours until doses of 12.5 mg/kg were achieved, but started at 1.5 mg/kg in the KHT sarcoma. Irradiating tumours 1 h after injecting plinabulin enhanced response in both models.
CONCLUSIONS: Plinabulin induced a time- and dose-dependent decrease in tumour perfusion. The KHT sarcoma was more sensitive than the C3H tumour to the anti-tumour effects of plinabulin, while radiation response was enhanced in both models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21815749      PMCID: PMC3509771          DOI: 10.3109/09553002.2011.605418

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  37 in total

Review 1.  Vascular damaging agents.

Authors:  D M Patterson; G J S Rustin
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-04-24       Impact factor: 4.126

Review 2.  Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

Authors:  Michael R Horsman; Dietmar W Siemann
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

3.  The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.

Authors:  Tomas Breidahl; Flemming U Nielsen; Hans Stødkilde-Jørgensen; Ross J Maxwell; Michael R Horsman
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

Review 4.  Disrupting tumour blood vessels.

Authors:  Gillian M Tozer; Chryso Kanthou; Bruce C Baguley
Journal:  Nat Rev Cancer       Date:  2005-06       Impact factor: 60.716

5.  Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.

Authors:  Thomas Nielsen; Rumi Murata; Ross J Maxwell; Hans Stødkilde-Jørgensen; Leif Ostergaard; Carsten D Ley; Paul E G Kristjansen; Michael R Horsman
Journal:  Acta Oncol       Date:  2010-10       Impact factor: 4.089

6.  Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.

Authors:  Carsten D Ley; Michael R Horsman; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

7.  NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.

Authors:  Benjamin Nicholson; G Kenneth Lloyd; Brian R Miller; Michael A Palladino; Yoshiaki Kiso; Yoshio Hayashi; Saskia T C Neuteboom
Journal:  Anticancer Drugs       Date:  2006-01       Impact factor: 2.248

Review 8.  Differentiation and definition of vascular-targeted therapies.

Authors:  Dietmar W Siemann; Michael C Bibby; Graham G Dark; Adam P Dicker; Ferry A L M Eskens; Michael R Horsman; Dieter Marmé; Patricia M Lorusso
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

9.  Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.

Authors:  Thomas Nielsen; Rumi Murata; Ross J Maxwell; Hans Stødkilde-Jørgensen; Leif Ostergaard; Michael R Horsman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

View more
  4 in total

1.  Synthesis of deuterium-enriched and fluorine-substituted plinabulin derivatives and evaluation of their antitumor activities.

Authors:  Zhongpeng Ding; Yingwei Hou; Shixiao Wang; Tianwen Sun; Mingxu Ma; Huashi Guan; Wenbao Li
Journal:  Mol Divers       Date:  2017-05-09       Impact factor: 2.943

Review 2.  Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

Authors:  Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

3.  Sulfated polymannuroguluronate TGC161 ameliorates leukopenia by inhibiting CD4+ T cell apoptosis.

Authors:  Chuanqin Shi; Wenwei Han; Meifang Zhang; Ruochen Zang; Kaixin Du; Li Li; Ximing Xu; Chunxia Li; Shixin Wang; Peiju Qiu; Huashi Guan; Jinbo Yang; Shuai Xiao; Xin Wang
Journal:  Carbohydr Polym       Date:  2020-07-06       Impact factor: 9.381

4.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.

Authors:  Thomas Nielsen; Thomas Wittenborn; Michael R Horsman
Journal:  Pharmaceutics       Date:  2012-11-07       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.